Ionis Pharmaceuticals Inc  

(Public, NASDAQ:IONS)   Watch this stock  
Find more results for NASDAQ:ISIS
+0.15 (0.32%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 46.01 - 47.01
52 week 19.59 - 57.00
Open 46.54
Vol / Avg. 0.00/1.62M
Mkt cap 5.71B
P/E     -
Div/yield     -
EPS -1.53
Shares 121.20M
Beta 2.54
Inst. own 91%
Feb 23, 2017
Q4 2016 Ionis Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jan 9, 2017
Ionis Pharmaceuticals Inc at JPMorgan Healthcare Conference
Jan 5, 2017
Ionis Pharmaceuticals Inc Pipeline Update Webcast
Dec 14, 2016
Ionis Pharmaceuticals Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - Webcast
Nov 29, 2016
Ionis Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 6.63% -31.12%
Operating margin 14.52% -26.70%
EBITD margin - -23.10%
Return on average assets 3.56% -9.27%
Return on average equity 23.51% -38.50%
Employees 428 -
CDP Score - -


2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President, Legal, General Counsel and Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
C. Frank Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 59
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 58
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 54
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters